Current clinical management and outcome of patients with adrenal cortical carcinoma (ACC) with rare histological subtypes—an ENSAT cohort study

Key Points

This research aims to evaluate the clinical management and outcomes of patients with different histological subtypes of adrenal cortical carcinoma.
Analyzed data from the ENSAT cohort specifically for adrenal cortical carcinoma patients.
Compared outcomes among various histological subtypes including oncocytic ACC.
Adjusted outcomes based on cancer stage to evaluate survival rates.
Oncocytic ACC demonstrated better stage-adjusted outcomes compared to other subtypes.
Survival rates varied significantly among different histological subtypes of adrenal cortical carcinoma.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Cohort study reports better stage-adjusted outcomes in oncocytic ACC, indicating a need for tailored management.

Stage-adjusted outcome in oncocytic ACC is better than in other subtypes.

No takes yet. Share an insight, caveat, or question.

Kimpel et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share